Internal Medicine

NCI-CCC GI Tumor Board Question

Questions discussed in this category

How would you approach a patient with imaging and labs suggestive of potentially resectable cholangiocarcinoma when several core biopsies reveal bridging fibrosis with no malignant cells?

1 Answer available

In patients with HCC and asymptomatic but endoscopically visible varices, how long do you wait to start bevacizumab after banding?

1 Answer available

What is the role of liver transplant in NET?

3 Answers available

What is your preferred second line therapy for an HCC patient who progressed after first line checkpoint inhibitor monotherapy?

Would you try atezolizumab/bevacizumab or switch to a TKI?

2 Answers available

Papers discussed in this category

The New England journal of medicine, 2018-07-05

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Lancet (London, England), 2018-03-24

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

J Gastroenterol, 2019 Nov 12

REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.

Am Heart J, 2010 Sep 18

Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.

N Engl J Med,

Sorafenib in advanced hepatocellular carcinoma.

Lancet (London, England), 2017-01-07

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology, 2019-02

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

JAMA Oncol, 2020 Dec 10

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.

Hepatology, 2019 Oct 14

Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.

Am J Transplant, 2016 Jun 09

The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors.

Transplantation, 2021 Apr 27

Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors.

Surgery, 2017 Jun 16

Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

Related Topics in Internal Medicine